Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 2
Submit an article Journal homepage
692
Views
40
CrossRef citations to date
0
Altmetric
Review

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

Giuseppe BronteUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Enrico BronteUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Giuseppina NovoUniversity of Palermo, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
,
Gianfranco PerniceUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Francesca Lo VulloUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Emmanuela MussoUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Fabrizio BronteUniversity of Palermo, Section of Gastroenterology, DiBiMIS, Palermo, Italy
,
Eliana GulottaUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Sergio RizzoUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Christian RolfoUniversity of Antwerp, University Hospital Antwerp, Oncology Department, Antwerp, Belgium
,
Nicola SilvestrisNational Cancer Research Centre - Istituto Tumori "Giovanni Paolo II", Medical Oncology Unit, Bari, Italy
,
Viviana BazanUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Salvatore NovoUniversity of Palermo, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
&
Antonio RussoUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy+ 39 091 6552500; + 39 091 6554529; [email protected]
, MD PhD (Professor) show all
Pages 253-267 | Published online: 13 Dec 2014

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Xin Lai, Qing Wan, Shou-Feng Jiao, Xiao-Chun Sun, Jin-Fang Hu & Hong-Wei Peng. (2023) Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study. Expert Opinion on Drug Safety 0:0, pages 1-10.
Read now

Articles from other publishers (39)

Ke Xu, Hao Tang, Jie Xiong, Xiaofang Ban, Yuchen Duan & Yingfeng Tu. (2023) Tyrosine kinase inhibitors and atherosclerosis: A close but complicated relationship. European Journal of Pharmacology 954, pages 175869.
Crossref
Jong Yoon Lee. (2023) Accurate Evaluation and Treatment of Dyspnea in Patients with Gastrointestinal Cancer. Journal of Digestive Cancer Research 11:2, pages 108-113.
Crossref
Tienush Rassaf & Dirk Schadendorf. 2023. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease 370 375 .
Avirup Guha, Prantesh Jain, Michael G. Fradley, Daniel Lenihan, Jahir M. Gutierrez, Chhavi Jain, Marcos de Lima, Jill S. Barnholtz‐Sloan, Guilherme H. Oliveira, Afshin Dowlati & Sadeer Al‐Kindi. (2021) Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries. Cancer Medicine 10:12, pages 3862-3872.
Crossref
Giuseppina Novo, Lorena Incorvaia, Laura Ajello, Enrico Bronte, Puja Mehta, Susmita Parashar, Salvatore Novo & Antonio Russo. 2021. Practical Medical Oncology Textbook. Practical Medical Oncology Textbook 309 325 .
Marina T Van Leeuwen, Steven Luu, Howard Gurney, Martin R Brown, Sallie-Anne Pearson, Kate Webber, Lee Hunt, Soojung Hong, Geoffrey P Delaney & Claire M Vajdic. (2020) Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. JNCI Cancer Spectrum 4:6.
Crossref
Karla B. Neves, Augusto C. MontezanoNinian N. LangRhian M. Touyz. (2020) Vascular toxicity associated with anti-angiogenic drugs. Clinical Science 134:18, pages 2503-2520.
Crossref
Giuseppina Novo, Daniela Di Lisi, Enrico Bronte, Francesca Macaione, Vincenzo Accurso, Giuseppe Badalamenti, Gaetana Rinaldi, Sergio Siragusa, Salvatore Novo & Antonio Russo. (2020) Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience. Oncology 98:7, pages 445-451.
Crossref
Austin Greco, Danish Safi, Umang Swami, Tim Ginader, Mohammed Milhem & Yousef Zakharia. (2019) Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. Cancers 11:12, pages 1950.
Crossref
Yongbing Sun, Wen Ma, Yuanyuan Yang, Mengxue He, Aimin Li, Lei Bai, Bin Yu & Zhiqiang Yu. (2019) Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian Journal of Pharmaceutical Sciences 14:6, pages 581-594.
Crossref
Raluca I. Mincu, Amir A. Mahabadi, Lars Michel, Simone M. Mrotzek, Dirk Schadendorf, Tienush Rassaf & Matthias Totzeck. (2019) Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors. JAMA Network Open 2:8, pages e198890.
Crossref
Carlo Gabriele TocchettiChristian CadedduDaniela Di LisiSaveria FemminòRosalinda MadonnaDonato MeleInes MonteGiuseppina NovoClaudia PennaAlessia PepePaolo SpallarossaGilda VarricchiConcetta ZitoPasquale PagliaroGiuseppe Mercuro. (2019) From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxidants & Redox Signaling 30:18, pages 2110-2153.
Crossref
Giuseppina Novo, Daniela Di Lisi, Enrico Bronte, Manuela Fiuza & Fausto J. Pinto. 2019. Cardiovascular Complications in Cancer Therapy. Cardiovascular Complications in Cancer Therapy 33 44 .
Enrico Bronte, Giuseppina Novo, Viviana Bazan, Christian Rolfo, Stefania Gori & Antonio Russo. 2019. Cardiovascular Complications in Cancer Therapy. Cardiovascular Complications in Cancer Therapy 205 217 .
Enrico Bronte, Giuseppe Bronte, Giuseppina Novo, Gaetana Rinaldi, Fabrizio Bronte, Francesco Passiglia & Antonio Russo. (2018) Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. Pharmacology & Therapeutics 192, pages 65-73.
Crossref
Xiu Hu, Lin-wen Wu, Zuo-yan Zhang, Meng-ling Chen, Yang-ling Li & Chong Zhang. (2018) The anti-tumor effect of regorafenib in lung squamous cell carcinoma in vitro. Biochemical and Biophysical Research Communications 503:2, pages 1123-1129.
Crossref
Gilda Varricchi, Pietro Ameri, Christian Cadeddu, Alessandra Ghigo, Rosalinda Madonna, Giancarlo Marone, Valentina Mercurio, Ines Monte, Giuseppina Novo, Paolo Parrella, Flora Pirozzi, Antonio Pecoraro, Paolo Spallarossa, Concetta Zito, Giuseppe Mercuro, Pasquale Pagliaro & Carlo G. Tocchetti. (2018) Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers in Physiology 9.
Crossref
Xinqiang Han, Yun Zhou & Wendi Liu. (2017) Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. npj Precision Oncology 1:1.
Crossref
M. A. Pellin, R. M. Wouda, K. Robinson, K. Tsimbas, I. D. Kurzman, B. J. Biller & D. M. Vail. (2017) Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study. Veterinary and Comparative Oncology 15:3, pages 919-931.
Crossref
Atai Watanabe, Kazuaki Yokoyama, Nobuhiro Ohno, Kaoru Uchimaru, Naohide Yamashita & Arinobu Tojo. (2017) Reversible Pulmonary Arterial Hypertension Induced by Dasatinib in a Patient With Chronic Myeloid Leukemia. Journal of Diagnostic Medical Sonography 33:4, pages 284-289.
Crossref
Daniela Di Lisi, Rosalinda Madonna, Concetta Zito, Enrico Bronte, Giuseppe Badalamenti, Paolo Parrella, Ines Monte, Carlo Gabriele Tocchetti, Antonio Russo & Giuseppina Novo. (2017) Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. International Journal of Cardiology 227, pages 11-17.
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 641 693 .
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 435 456 .
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 395 414 .
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 283 304 .
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 167 197 .
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 81 93 .
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 3 7 .
E. Bronte, A. Galvano, G. Novo & A. Russo. 2017. Cardio-Oncology. Cardio-Oncology 69 89 .
Paul J. Davis & Shaker A. Mousa. 2017. Anti-Angiogenesis Strategies in Cancer Therapeutics. Anti-Angiogenesis Strategies in Cancer Therapeutics 125 131 .
Barbara Bassani, Antonino Bruno, Nicoletta Macrì, Paola Corradino, Douglas M. Noonan & Adriana Albini. 2017. Manual of Cardio-oncology. Manual of Cardio-oncology 107 122 .
Elisabetta Grillo, Cosetta Ravelli, Michela Corsini, Kurt Ballmer-Hofer, Luca Zammataro, Pasqua Oreste, Giorgio Zoppetti, Chiara Tobia, Roberto Ronca, Marco Presta & Stefania Mitola. (2016) Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. Oncotarget 7:23, pages 35353-35368.
Crossref
Giuseppina Novo, Christian Cadeddu, Vincenzo Sucato, Pasquale Pagliaro, Silvio Romano, Carlo G. Tocchetti, Concetta Zito, Luca Longobardo, Savina Nodari & Maria Penco. (2016) Role of biomarkers in monitoring antiblastic cardiotoxicity. Journal of Cardiovascular Medicine 17, pages e27-e34.
Crossref
Nicola Maurea, Carmela Coppola, Giovanna Piscopo, Francesca Galletta, Gennaro Riccio, Emanuela Esposito, Claudia De Lorenzo, Michelino De Laurentiis, Paolo Spallarossa & Giuseppe Mercuro. (2016) Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. Journal of Cardiovascular Medicine 17, pages e19-e26.
Crossref
Lorena Incorvaia, Giuseppe Bronte, Viviana Bazan, Giuseppe Badalamenti, Sergio Rizzo, Gianni Pantuso, Clara Natoli & Antonio Russo. (2016) Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget 7:16, pages 21259-21271.
Crossref
Lauren Caldemeyer, Michael Dugan, John Edwards & Luke Akard. (2016) Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 11:2, pages 71-79.
Crossref
P. Debourdeau, A. Stancu, V. Debourdeau & D. Serin. (2016) Allongement de l’intervalle QT secondaire aux inhibiteurs des tyrosines-kinasesProlongation of the Secondary QT Interval with Tyrosine-Kinase Inhibitors. Oncologie 18:1, pages 47-54.
Crossref
Enrico Bronte, Giuseppe Bronte, Giuseppina Novo, Fabrizio Bronte, Maria Grazia Bavetta, Giuseppe Lo Re, Giuseppe Brancatelli, Viviana Bazan, Clara Natoli, Salvatore Novo & Antonio Russo. (2015) What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget 6:34, pages 35589-35601.
Crossref
Kimberly-Ann BordunSheena PremeczMegan daSilvaSoma MandalVineet GoyalTamara GlavinovicMatthew CheungDavid CheungChristopher W. WhiteRakesh ChaudharyDarren H. FreedHector R. VillarragaJoerg HerrmannManish KohliAmir RavandiJames ThliverisMarshall Pitz, Pawan K. SingalSharon MulvaghDavinder S. Jassal. (2015) The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. American Journal of Physiology-Heart and Circulatory Physiology 309:4, pages H692-H701.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.